Research brief · 2026-09-09
How to Read a Clinical Trial
A clinical trial is built around one question chosen before it starts. That is the primary endpoint, and it is meant to be locked into a public registration so it cannot be swapped for a better-looking result later. Reading a trial well starts with finding it, because it is the only result the trial was sized to detect. Everything else is secondary, and secondary results do not carry the same weight even when a headline treats them that way.
Tesamorelin is a prescription medication approved for HIV-associated abdominal fat, and decisions about it belong with a physician. In 2007, Falutz and colleagues published in the New England Journal of Medicine a trial that randomized 412 people with HIV and abdominal fat accumulation to tesamorelin or placebo. The primary endpoint was percent change in visceral fat by CT scan at 26 weeks. It fell 15.2 percent on tesamorelin and rose 5.0 percent on placebo, P less than 0.001.
Next, check every endpoint. A 2010 pooled analysis in the Journal of Clinical Endocrinology and Metabolism combined 806 patients from two Phase 3 trials. Visceral fat and triglycerides fell significantly. Subcutaneous fat, in the same table, changed by minus 0.6 percent and missed significance. The effect was specific to one fat compartment. The safety table matters too: more patients on tesamorelin withdrew because of an adverse event. And a 2008 extension in AIDS found the visceral fat loss held through 52 weeks on treatment but reaccumulated once the drug stopped.
What none of these trials show is whether a smaller fat measurement on a scan lowers heart attacks, strokes or death. Visceral fat here is a surrogate endpoint, a stand-in assumed to track harder outcomes, and that assumption needs its own evidence. The population was 86 percent male with HIV, and follow-up stopped at one year. For any decision about a prescription medication, talk to a physician. Sources are listed below.
Sources
- Falutz J et al., Metabolic effects of a growth hormone-releasing factor in patients with HIV (n=412)
- New England Journal of Medicine, 2007
- Falutz J et al., Effects of tesamorelin in HIV-infected patients with excess abdominal fat: pooled analysis of two Phase 3 trials (n=806)
- Journal of Clinical Endocrinology & Metabolism, 2010
- Falutz J et al., Long-term safety and effects of tesamorelin in HIV patients with abdominal fat accumulation (n=410)
- AIDS, 2008
Peptide Proof reports what studies found. We do not give medical advice, dosing guidance, or treatment recommendations.